Organisation paid for research Program year 2024 Source: CMS Open Payments

Tri State Urologic Services PSC, Inc

Neither a doctor nor a teaching hospital

Research payments

$346,089

306 payments

Through program year 2024, Tri State Urologic Services PSC, Inc is reported as receiving $346,089 in research payments, across 306 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2024	Research	$51,373	32
2023	Research	$261,466	254
2022	Research	$33,250	20

Breakdown

Who paid Research payments · program years 2022–2024

Bayer HealthCare Pharmaceuticals Inc. $346,089 306 payments

Studies the money was for Research payments · program years 2022–2024

Open-label external control arm study of darolutamide plus A $288,388 267 payments
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC $49,604 30 payments
Darolutamide Roll Over Study $6,328 7 payments
BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies $1,769 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.